Reported recurrence rates of lentigo maligna treated with Mohs micrographic surgery have ranged from 0.5 to 30.0% in the ...
As part of The Wistar Institute's Melanoma Research Center, the Villanueva lab pursues new ways to overcome the challenge of melanoma drug resistance. In this paper, the group took aim at melanomas ...
Basal cell carcinomas, the most common form of skin cancer, occur in chronically sun-exposed areas such as the face. Locally advanced tumors in particular can be difficult to treat surgically. A ...
The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant ...
2d
News Medical on MSNInhibiting S6K2 gene offers potential treatment for drug-resistant melanomaThe lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .
Learn how melanoma impacts African Americans, highlighting detection challenges, survival disparities, and prevention ...
A WOMAN has shared how she found a worryingly small early symptom of cancer on her husband’s toenail – which was dismissed by doctors as a fungal infection. David Edges wasn’t concerned when a ...
More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.Researchers identified several risk factors, including older age, ...
The following is a summary of “Skin cancer risk in over 200.000 patients with haematologic malignancies in 30 years; a ...
STOCKHOLM, Jan. 28, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that a new ...
After the surgery on the side of my head, I had immunotherapy treatment with ... lesion turned out to be a malignant melanoma — the most dangerous type of skin cancer. Farahnik called the ...
As part of The Wistar Institute’s Melanoma Research Center, the Villanueva lab pursues new ways to overcome the challenge of melanoma drug resistance. In this paper, the group took aim at melanomas ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results